Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Blood (2017) 130 (Supplement 1): 737.

https://doi.org/10.1182/blood.V130.Suppl_1.737.737

Published: 2017

Journal Articles

Beacoppescalated Followed By Radiotherapy of Initial Bulk or Residual Disease in Advanced Stage Hodgkin Lymphoma: Long-Term Follow up of the HD9 and HD12 Trials of the German Hodgkin Study Group

Stefanie Kreissl, MD, Bastian von Tresckow, MD, Helen Goergen, PhD, Heinz Haverkamp, Stephanie Sasse, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2016) 128 (22): 923.

https://doi.org/10.1182/blood.V128.22.923.923

Published: 2016

Journal Articles

Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group

Dennis A. Eichenauer, MD, Helen Goergen, Annette Pluetschow, Karolin Behringer, MD, Stefanie Kreissl, MD, Paul Bröckelmann, MD, Michael Fuchs, MD, Boris Böll, MD, Bastian von Tresckow, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2015) 126 (23): 2729.

https://doi.org/10.1182/blood.V126.23.2729.2729

Published: 2015

Journal Articles

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Pluetschow, Heinz Haverkamp, Stefanie Kreissl, MD, Michael Fuchs, Martin Soekler, Johannes C. Hellmuth, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, Carsten Kobe, Volker Diehl, MD, Andreas Engert

Blood (2015) 126 (23): 580.

https://doi.org/10.1182/blood.V126.23.580.580

Published: 2015

Journal Articles

Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Stefanie Kreissl, MD, Helen Goergen, Bastian von Tresckow, MD, Karolin Behringer, MD, Jana Markova, MD, Andreas Lohri, MD, Julia Meissner, MD, Josée M Zijlstra, MD, Richard Greil, MD, Max S. Topp, MD, Martin Sökler, MD, Hartmut Döhner, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2015) 126 (23): 3941.

https://doi.org/10.1182/blood.V126.23.3941.3941

Published: 2015

Journal Articles

Fatigue in Hodgkin Lymphoma Patients: Longitudinal Evaluation and Curve Types up to 5 Years

Stefanie Kreissl, MD, Horst Mueller, PhD, Axel Mayer, Karolin Behringer, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2014) 124 (21): 854.

https://doi.org/10.1182/blood.V124.21.854.854

Published: 2014

Journal Articles

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

Peter Borchmann, MD, Heinz Haverkamp, Andreas Lohri, MD, Stefanie Kreissl, MD, Richard Greil, MD, Jana Markova, MD, Michaela Feuring-Buske, MD, Julia Meissner, MD, Ulrich Dührsen, Nicole Engel, MD, Ulrich Keller, MD, Georg Maschmeyer, MD, Markus Dietlein, MD, Carsten Kobe, MD, Michael Fuchs, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2014) 124 (21): 500.

https://doi.org/10.1182/blood.V124.21.500.500

Published: 2014

Journal Articles

Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Plütschow, PhD, Stefanie Kreissl, MD, Michael Fuchs, MD, Martin Soekler, MD, Nicole Engel, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, MD, Carsten Kobe, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2013) 122 (21): 4344.

https://doi.org/10.1182/blood.V122.21.4344.4344

Published: 2013

NARROW

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Beacoppescalated Followed By Radiotherapy of Initial Bulk or Residual Disease in Advanced Stage Hodgkin Lymphoma: Long-Term Follow up of the HD9 and HD12 Trials of the German Hodgkin Study Group

Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Fatigue in Hodgkin Lymphoma Patients: Longitudinal Evaluation and Curve Types up to 5 Years

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only